The Journal of Bone and Joint Surgery (American). 2007;89:1449-1451.
doi:10.2106/JBJS.F.00651
© 2007 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the activities for this article:
CME 3: July, August, September 2007 (publication date October 5, 2007; expi...
Shoulder/Elbow Test 20: Fall 2007 (publication date November 15, 2007; expi...
Right arrow [Supplementary Material]
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanchez-Sotelo, J.
Right arrow Articles by Morrey, B. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sanchez-Sotelo, J.
Right arrow Articles by Morrey, B. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

Ninety-Day Mortality After Total Elbow Arthroplasty

Joaquin Sanchez-Sotelo, MD, PhD1, John W. Sperling, MD1 and Bernard F. Morrey, MD1

1 Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for J. Sanchez-Sotelo: sanchezsotelo.joaquin{at}mayo.edu

Investigation performed at the Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota

Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. One or more of the authors, or a member of his or her immediate family, received, in any one year, payments or other benefits in excess of $10,000 or a commitment or agreement to provide such benefits from a commercial entity (Zimmer). No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of their immediate families, are affiliated or associated.


Background: Perioperative mortality, although seldom mentioned and rare after upper-extremity surgery, is one of the potential complications of total elbow arthroplasty. The purpose of this study was to determine the prevalence and risk factors associated with perioperative mortality after elbow arthroplasty.

Methods: The records of 1117 consecutive patients who had undergone 1441 total elbow arthroplasties at our institution between 1970 and 2002 were reviewed to identify patients who had died within ninety days after the procedure. A detailed analysis of the medical, surgical, anesthetic, and pathologic records of these patients was performed.

Results: The ninety-day mortality rate was 0.62% (nine of 1441 cases). Seven of the patients who died were female and two were male; their mean age at the time of surgery was sixty-six years. An underlying diagnosis of distal humeral fracture (including pathologic fracture) or nonunion was associated with an increased risk of death (p < 0.001). Seven patients died after primary arthroplasty and two, after revision arthroplasty. The average time from surgery to death was forty-five days. The causes of death were congestive heart failure (three patients) and myocardial infarction, acute heart embolus, respiratory failure, pneumonia, renal failure, and bleeding secondary to gastric stress ulcer (one patient each). All patients had substantial comorbidities.

Conclusions: The rate of perioperative mortality after total elbow arthroplasty is low. Most patients who die after this procedure are elderly, have substantial comorbidities, and underwent the total elbow arthroplasty for the treatment of a traumatic or pathologic distal humeral fracture or nonunion.

Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?